With Increased Focus on MDx, Tm Assays Help Drive Luminex’s 32 Percent Q2 Revenue Growth | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
Luminex last week reported a 32 percent increase in second-quarter revenues with a significant contribution coming from a cystic fibrosis assay developed by Tm Bioscience, which Luminex acquired for $44 million earlier this year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.